Efficacy and Dose Adjustment of Oral Desmopressin (DDAVP) in Patients with Central Diabetes Insipidus

中樞性尿崩症（central diabetes insipidus, CDI）是因為缺乏抗尿激素（ADH）－即一罕見的疾病，它會導致體內水份無法保留而現多尿頻渴之臨床症狀。Desmopressin（1-desamino-8-D-arginine-vasopressin, dDAVP）是一類似ADH的合成物質，在臨床使用上，已超過二十年。目八是治療中樞性尿症最有效的藥物，而經由鼻腔投與每天二至三次是典型的給藥方式。近來，證實dDAVP經由口服投與，也具有抗利尿活性。我們提出兩個中樞性尿症病例報告，一為肺癌轉移引起，另一為原發性。給予口服的dDAVP錠劑並經過適當的調整劑後，它可安全有效的控制中樞性尿崩症病患的水份平衡。

關鍵字

中樞性尿崩症；肺癌；水份剝奪試驗； dDAVP（Desmopressin）錠劑

並列摘要

Central diabetes insipidus (CDI) is an uncommon disease caused by the deficiency of antidiuretic hormone (ADH), i.e. vasopressin. Deficiency of ADH leads to a failure to conserve water and results in polyuria and polydipsia. Desmopressin (1-desamino-8-Darginine vasopressin, dDAVP), a synthetic analogue of vasopressin, has been utilized for over 20 years, it is the most effective drug for the management of CDI and is adminosered typically by intranasal route one to three times daily. Recently, dDAVP was proven to be effective when given orally. The experience of treating CDI with oral dDAVP is limited in Taiwan. We hereby reported two cases of CDI, one was caused by metastatic lung cancer and the other was idiopathic. These two cases responded to administration of oral dDAVP without notable side-effects. In this report, we shared our experience in dosage adjustment of dDAVP that was critical for successful treatment. The pharmacokinetic characteristics of oral dDAVP were also discussed in this report.

並列關鍵字

central diabetes insipidus (CDI) ； water deprivation test ； desmopressin (dDAVP) tablet

國際替代計量

Efficacy and Dose Adjustment of Oral Desmopressin (DDAVP) in Patients with Central Diabetes Insipidus

全文下載

主題瀏覽